title: Expression of MAGE A1-6 and the clinical characteristics of papillary thyroid carcinoma.
abstract: BACKGROUND
  The expression of melanoma-associated antigen (MAGE) gene has been studied in many types of cancer. In the present study we evaluated the correlation between MAGE expression and the clinical features and oncologic outcomes of patients with papillary thyroid cancer (PTC).
  
  
  METHODS
  We performed a retrospective review of 85 patients who underwent surgery for PTC and analysis of their tumor tissue by nested reverse transcription-polymerase chain reaction (RT-PCR) with the MAGE common primer to detect the MAGE A1-6 gene. The associations between MAGE expression and clinical characteristics were analyzed.
  
  
  RESULTS
  Expression of MAGE A1-6 in PTC was identified in 31 patients (36.5%). Only papillary thyroid microcarcinoma (PTMC) was significantly related to MAGE expression in our univariate analysis (p=0.002) and multivariate analysis (p=0.006). MAGE had no significant impact on survival.
  
  
  CONCLUSIONS
  Expression of MAGE A1-6 in PTC is significantly correlated with the presence of PTMC. Our study suggests that MAGE expression may be related to early-stage PTC.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine, Busan, South Korea.
authors.forename: Hyoung Shin
authors.initials: HS
authors.lastname: Lee
authors.forename: Sung Won
authors.initials: SW
authors.lastname: Kim
authors.forename: Jong Chul
authors.initials: JC
authors.lastname: Hong
authors.forename: Sang Bong
authors.initials: SB
authors.lastname: Jung
authors.forename: Chang-Ho
authors.initials: CH
authors.lastname: Jeon
authors.forename: Jong Wook
authors.initials: JW
authors.lastname: Park
authors.forename: Sung Young
authors.initials: SY
authors.lastname: Park
authors.forename: Kang Dae
authors.initials: KD
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000235:genetics; D014408:Biomarkers, Tumor / Q000235:genetics*; D002291:Carcinoma, Papillary / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D058950:Melanoma-Specific Antigens / Q000235:genetics*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D055815:Young Adult
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C072011:MAGEA1 protein, human; C072013:MAGEA3 protein, human; C095204:MAGEA4 protein, human; C095203:MAGEA6 protein, human; C420909:Mage-a2 antigen; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D012333:RNA, Messenger